Phenomix Medicine Announces NEO-MRD, China's First CE-Certified and IVD Clinical Trial-Entered High-Sensitivity MRD Detection Product for Hematologic Malignancies
Minimal Residual Disease (MRD) refers to the presence of residual cancer cells in patients who have achieved clinical remission following treatment, serving as the root cause of disease recurrence.. In clinical practice, MRD testing can assess the risk level of diseaseStratification, Guided Therapy, and Determination of the Optimal Timing for Bone Marrow Transplantation, and pre-Assessing the Risk of Recurrence After Treatmentetc.
For hematologic malignancies such as acute lymphoblastic leukemia, multiple myeloma, and lymphoma, MRD status is a reliable indicator for assessing treatment efficacy and clinical outcomes.Applying Accurate and Sensitive MRD Detection Technology to the Full-Cycle Treatment Management of Patients with Hematologic Malignancies, which can significantly improve the prognosis of patients with hematologic malignancies.
Shenzhen Fanyin Medical Co., Ltd.(hereinafter referred to as "PanGene Medicine")Independently Developed“NEO-MRD” MRD Testing Product for Hematologic Malignancies, isChina's FirstEntering IVD Registration Clinical TrialsMRD testing products for hematologic malignancies, and alsoThe First CE-Certified in Chinaof blood cancer MRD testing products. The NGS-MRD detection capability of this product has reached an internationally leading level, with over ten thousand clinical samples accumulated in its database. It ranks among the top domestic products in its category and fills a gap in China’s relevant field.
On Monday, September 9 at 19:30, the 92nd session of VCBeat’s New Product Showcase will feature Wu Jinghua, CTO of Shenzhen Fanyin Medical Co., Ltd., who will present“Ultra-High-Sensitivity MRD Detection Product for Hematologic Malignancies——NEO-MRD”Product Introduction.
NEO-MRD: Detection of Minimal Residual Disease in Hematologic Malignancies
Technical Originality: Independently Developed
Product Features:Detection of Minimal Residual Disease in Lymphoid Hematologic Malignancies
Solution Pathway: Tumor Clone Identification and MRD Detection Based on an Accurate, Unbiased Ig/TCR Multiplex PCR Assay System.
Product-related patents: 4 granted;Related Software Copyrights: 5 Approved
Application Areas: Risk stratification for patients with hematologic malignancies, efficacy assessment, determination of the optimal timing for transplantation, prediction of early relapse, and feasibility of non-invasive testing in peripheral blood.
Innovations in Design and Therapy: Immune Repertoire NGS Methods with Sensitivity Reaching10⁻⁶, which is more sensitive than traditional flow cytometry100x。
Breakthrough Impact on Traditional Medical Practices:NGS-MRD testing has reached an internationally leading level, filling a domestic gap in this field.。
Leveraging products and services for MRD testing in hematologic malignancies, immunotherapy testing for hematologic malignancies, and autoimmune disease testing,PanGen MedicineHas established collaborations with more than 40 hospitals, over 20 distributors, and more than 20 CAR-T companies.。
Scan the QR code on the poster to add our assistant and schedule a live stream.
Wu Jinghua
CTO, Shenzhen Fanyin Medical Co., Ltd.
Ph.D. in Genomics from the University of Chinese Academy of Sciences, with over 10 years of experience in scientific research and technological development in immunogenomics; authored more than 20 SCI-indexed papers and filed over 20 patent applications.
About PanYin Medicine
Shenzhen FanYin Medicine Co., Ltd. (hereinafter referred to as “FanYin Medicine”) is a premier provider of data and technical support in the field of precision medicine based on immunomics. The company has been successively recognized as an Innovative Small and Medium-sized Enterprise in Shenzhen, a National High-Tech Enterprise, and a Specialized, Refined, Differential, and Innovative Small and Medium-sized Enterprise in Shenzhen. Deeply rooted in the field of immunomics, FanYin Medicine leverages its accurate and sensitive FAIR-SEQ platform, high-throughput antigen-specific TCR/BCR screening platform, proprietary immunomics data analysis software, and large-scale clinical immunology database. The company is primarily engaged in the research and development of products and the provision of technical services related to hematologic malignancy detection and minimal residual disease (MRD) monitoring, companion diagnostics for immunotherapy, assessment of immune system recovery during disease treatment, and TCR and antibody drug screening.
About New Product Reviews by VCBeat
“Artery New Product Showcase” is a live-streaming series dedicated to supporting medical enterprises in launching innovative products. The mission of the series is to facilitate the milestone launch of every innovative medical product. If your company plans to release an innovative medical product or achieve a significant milestone and wishes to participate in the “Artery New Product Showcase,” please add our assistant for consultation.
Method 1: Watch the live stream via the Mini Program
Scan the QR code below to contact the assistant and schedule a live stream (if already added, please proactively reach out to the assistant).
Option 2: Watch the live stream on the VCBeat app for a chance to win exciting prizes
Scan the QR code below to download the VCBeat app and register to watch the live stream.
Send a screenshot of the live stream to the assistant to enter the lucky draw for a chance to win a [15-day trial membership of VBInsight Industry Think Tank].
